AI Article Synopsis
- The study explored the effectiveness of fludarabine and cytarabine in treating relapsed acute myeloid leukemia (AML) patients who didn't respond to initial salvage therapy.
- Complete remission (CR) was achieved in 39% of patients overall, with a higher success rate of 47% in those with favorable/intermediate-risk karyotypes.
- Median overall survival for patients achieving CR was 9.6 months compared to 4.5 months for non-responders, indicating that fludarabine-cytarabine should be further studied for this patient group.
Article Abstract
The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established. We evaluated the efficacy and toxicity of fludarabine and cytarabine in patients with AML in first relapse who did not respond to a course of salvage chemotherapy with mitoxantrone and etoposide. CR was achieved in 39 % of treated patients, and in 47 % of patients with a favorable/intermediate-risk karyotype. The median overall survival was 4.75 months. The median survival for patients achieving CR with fludarabine-cytarabine was significantly higher than for those who did not respond to therapy (9.6 vs. 4.5 months, P = 0.04). Our data suggest that the fludarabine-cytarabine regimen merits further investigation in relapsed AML patients with favorable or intermediate-risk karyotype with persistent leukemia after a course of salvage therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-012-1192-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!